Subscribe or Manage Preferences

Rheumatoid Arthritis

Leslie R. Harrold, MD, Associate Professor, Orthopedics and Physical Rehabilitation, University of Massachusetts Medical School, Worcester, and colleagues sought to determine how rituximab affects outcomes self-reported by patients by analyzing data from a cohort of 667 patients with RA who were enrolled in the US Corrona RA Registry.

In this study, the investigators analyzed baseline data from 176 patients with RA enrolled in the Evaluation of Subclinical Cardiovascular Disease and Predictors of Events in RA cohort study from October 2004 to May 2006.

A recently published report has shown that individually tailored behavioral interventions comprised of motivational counseling and text message reminders may effectively reduce daily sedentary time in patients with rheumatoid arthritis.

Dr Verstappen and colleagues had previously shown that patients treated within 6 months of symptom onset had improved 10-year outcomes compared with those who were treated later.

The efficacy of tocilizumab in combination with methotrexate and as monotherapy was maintained for 2 years in patients with early rheumatoid arthritis (RA), according to an analysis of the results of the FUNCTION trial (Burmester G, et al. Ann Rheum Dis. 2017. Epub ahead of print). No new safety signals associated with tocilizumab were reported with longer- term follow-up of this trial.
Washington, DC—In recent decades, the increased use of biologic agents has changed the way patients with rheumatoid arthritis are treated. At the 2016 Annual Meeting of the American College of Rheumatology, James R. O’Dell, MD, Bruce Professor and Vice Chair, Internal Medicine, and Chief Division of Rheumatology, University of Nebraska Medical Center, Omaha, discussed the impact these advances have on the management of rheumatoid arthritis.
In patients with rheumatoid arthritis (RA), fatigue is a significant predictor of high healthcare costs, reduced physical functioning, and poor quality of life. Fatigue has also been shown to persist in this patient population, even when disease remission is achieved, according to the results of a recent study.
Elderly patients (aged ≥60 years) with rheumatoid arthritis (RA) may be less likely to receive treatment with tumor necrosis factor (TNF) inhibitors than younger patients with RA because of concerns about comorbidities and adverse events. However, a new study by Soo-Kyung Cho, MD, PhD, Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, and colleagues shows that elderly patients who are prescribed these drugs have retention rates comparable to those of younger patients.
Women with rheumatoid arthritis (RA) had a 40% greater risk for mortality than women without RA during 36 years of follow-up in a longitudinal cohort study.
Although most patients with rheumatoid arthritis (RA) are satisfied with their prescribed treatment, many would like to change various aspects of their medication, according to the results of an online patient survey.
Page 3 of 9
Results 21 - 30 of 83
  • Rheumatology Practice Management
  • Lynx CME
  • American Health & Drug Benefits
  • Value-Based Cancer Care
  • Value-Based Care in Myeloma
  • Value-Based Care in Neurology